Src homology phosphotyrosyl phosphatase-2 expression is an independent negative prognostic factor in human breast cancer

Histopathology

Volumn 63, Issue 1, 2013, Pages 74-82

  Muenst, Simone ^a,b   Obermann, Ellen C ^a   Gao, Feng ^b   Oertli, Daniel ^c   Viehl, Carsten T ^c   Weber, Walter P ^c   Fleming, Timothy ^b   Gillanders, William E ^b   Soysal, Savas D ^b,c  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Breast cancer; Prognostic factor; PTPN11; SHP2

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; PROTEIN TYROSINE PHOSPHATASE SHP 2;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER PROGNOSIS; CANCER SURVIVAL; CANCER TISSUE; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SRC HOMOLOGY DOMAIN; TISSUE MICROARRAY;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; PROGNOSIS; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 11;

EID: 84879464179     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/his.12140     Document Type: Article

References (26)

1. Jiang ZX, Zhang ZY. Targeting PTPS with small molecule inhibitors in cancer treatment. Cancer Metastasis Rev. 2008; 27; 263-272.
2. Hatakeyama M. Oncogenic mechanisms of the Helicobacter pylori CagA protein. Nat. Rev. Cancer 2004; 4; 688-694.
3. Zhou X, Coad J, Ducatman B, Agazie YM. SHP2 is up-regulated in breast cancer cells and in infiltrating ductal carcinoma of the breast, implying its involvement in breast oncogenesis. Histopathology 2008; 53; 389-402.
4. Furcht CM, Munoz Rojas AR, Nihalani D, Lazzara MJ. Diminished functional role and altered localization of SHP2 in non-small cell lung cancer cells with EGFR-activating mutations. Oncogene 2012; 32; 2346 - 2355.
5. Quintanar-Audelo M, Yusoff P, Sinniah S, Chandramouli S, Guy GR. Sprouty-related ENA/vasodilator-stimulated phosphoprotein homology 1-domain-containing protein (SPRED1), a tyrosine-protein phosphatase non-receptor type 11 (SHP2) substrate in the RAS/extracellular signal-regulated kinase (ERK) pathway. J. Biol. Chem. 2011; 286; 23102-23112.
6. Aceto N, Sausgruber N, Brinkhaus H et al. Tyrosine phosphatase SHP2 promotes breast cancer progression and maintains tumor-initiating cells via activation of key transcription factors and a positive feedback signaling loop. Nat. Med. 2012; 18; 529-537.
7. Chan G, Kalaitzidis D, Neel BG. The tyrosine phosphatase SHP2 (PTPN11) in cancer. Cancer Metastasis Rev. 2008; 27; 179-192.
8. Tartaglia M, Niemeyer CM, Fragale A et al. Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia. Nat. Genet. 2003; 34; 148-150.
9. Mohi MG, Neel BG. The role of SHP2 (PTPN11) in cancer. Curr. Opin. Genet. Dev. 2007; 17; 23-30.
10. Ostman A, Hellberg C, Bohmer FD. Protein-tyrosine phosphatases and cancer. Nat. Rev. Cancer 2006; 6; 307-320.
11. Bard-Chapeau EA, Li S, Ding J et al. PTPN11/SHP2 acts as a tumor suppressor in hepatocellular carcinogenesis. Cancer Cell 2011; 19; 629-639.
12. Zhou X, Agazie YM. Molecular mechanism for SHP2 in promoting HER2-induced signaling and transformation. J. Biol. Chem. 2009; 284; 12226-12234.
13. Zhou XD, Agazie YM. Inhibition of SHP2 leads to mesenchymal to epithelial transition in breast cancer cells. Cell Death Differ. 2008; 15; 988-996.
14. Bentires-Alj M, Gil SG, Chan R et al. A role for the scaffolding adapter GAB2 in breast cancer. Nat. Med. 2006; 12; 114-121.
15. Bocanegra M, Bergamaschi A, Kim YH et al. Focal amplification and oncogene dependency of GAB2 in breast cancer. Oncogene 2010; 29; 774-779.
16. Bubendorf L, Nocito A, Moch H, Sauter G. Tissue microarray (TMA) technology: miniaturized pathology archives for high-throughput in situ studies. J. Pathol. 2001; 195; 72-79.
17. Tapia C, Schraml P, Simon R et al. HER2 analysis in breast cancer: reduced immunoreactivity in FISH non-informative cancer biopsies. Int. J. Oncol. 2004; 25; 1551-1557.
18. Perou CM, Sorlie T, Eisen MB et al. Molecular portraits of human breast tumours. Nature 2000; 406; 747-752.
19. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn HJ. Strategies for subtypes - dealing with the diversity of breast cancer: highlights of the St. Gallen international expert consensus on the primary therapy of early breast cancer 2011. Ann. Oncol. 2011; 22; 1736-1747.
20. Yu DH, Qu CK, Henegariu O, Lu X, Feng GS. Protein-tyrosine phosphatase SHP-2 regulates cell spreading, migration, and focal adhesion. J. Biol. Chem. 1998; 273; 21125-21131.
21. Agazie YM, Hayman MJ. Molecular mechanism for a role of SHP2 in epidermal growth factor receptor signaling. Mol. Cell. Biol. 2003; 23; 7875-7886.
22. Ferrari E, Tinti M, Costa S et al. Identification of new substrates of the protein-tyrosine phosphatase PTP1B by Bayesian integration of proteome evidence. J. Biol. Chem. 2011; 286; 4173-4185.
23. Agazie YM, Movilla N, Ischenko I, Hayman MJ. The phosphotyrosine phosphatase SHP2 is a critical mediator of transformation induced by the oncogenic fibroblast growth factor receptor 3. Oncogene 2003; 22; 6909-6918.
24. Ralston A, Rossant J. How signaling promotes stem cell survival: trophoblast stem cells and SHP2. Dev. Cell 2006; 10; 275-276.
25. Bentires-Alj M, Paez JG, David FS et al. Activating mutations of the Noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia. Cancer Res. 2004; 64; 8816-8820.
26. Yu ZH, Chen L, Wu L, Liu S, Wang L, Zhang ZY. Small molecule inhibitors of SHP2 tyrosine phosphatase discovered by virtual screening. Bioorg. Med. Chem. Lett. 2011; 21; 4238-4242.